Bourgeon Capital Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Bourgeon Capital Management’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-5,627	Closed	-$13K	–	289
2023 Q4	$13K	Hold	5,627	–	–	﹤0.01%	233
2023 Q3	$14.7K	Hold	5,627	–	–	﹤0.01%	217
2023 Q2	$20.1K	Hold	5,627	–	–	﹤0.01%	211
2023 Q1	$12.3K	Hold	5,627	–	–	﹤0.01%	224
2022 Q4	$67.7K	Hold	5,627	–	–	0.02%	138
2022 Q3	$36K	Hold	5,627	–	–	0.01%	148
2022 Q2	$26K	Hold	5,627	–	–	0.01%	167
2022 Q1	$49K	Hold	5,627	–	–	0.01%	143
2021 Q4	$80K	Hold	5,627	–	–	0.02%	133
2021 Q3	$124K	Hold	5,627	–	–	0.03%	120
2021 Q2	$75K	Hold	5,627	–	–	0.02%	146
2021 Q1	$57K	Hold	5,627	–	–	0.01%	156
2020 Q4	$24K	Hold	5,627	–	–	0.01%	171
2020 Q3	$15K	Hold	5,627	–	–	﹤0.01%	196
2020 Q2	$20K	Hold	5,627	–	–	0.01%	163
2020 Q1	$17K	Hold	5,627	–	–	0.01%	157
2019 Q4	$29K	Hold	5,627	–	–	0.01%	136
2019 Q3	$18K	Buy	+5,627	New	+$18.7K	0.01%	154

Other funds holding ORMP

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bourgeon Capital Management's ORMP Position: Q1 2024 in Review

Bourgeon Capital Management sold out of Oramed Pharmaceuticals (ORMP) in Q1 2024, closing a stake of 5,627 shares — an estimated $13K sold.

Bourgeon Capital Management first reported a position in ORMP in Q3 2019 and held it in 18 quarters. The position peaked at $124K in Q3 2021. 51 funds tracked by Wall St. Rank hold ORMP as of Q1 2024.

Bourgeon Capital Management reported no remaining Oramed Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Bourgeon Capital Management sold 5,627 Oramed Pharmaceuticals shares in Q1 2024, an estimated $13K.
Bourgeon Capital Management first reported a position in Oramed Pharmaceuticals in Q3 2019 and held it in 18 quarters.
Bourgeon Capital Management's Oramed Pharmaceuticals position peaked at $124K in Q3 2021.
51 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2024.

Based on Bourgeon Capital Management's 13F filing for Q1 2024, filed 19 Apr 2024.